NEW YORK (awp international) – New records are set for the US technology exchange Nasdaq on Friday. In contrast, the standard value indices are still lacking momentum to overcome the previous highs.
Over half an hour before the start of trading, broker IG rated the technology-heavy Nasdaq 100 index 0.50 percent higher to 16,565 points. On a weekly basis, it is heading towards a plus of over two percent, and since the beginning of the year there has even been a hefty price gain of almost 29 percent.
In contrast, IG estimated the Dow Jones Industrial on Friday 0.54 percent lower to 35,677 points, which is a weekly minus of more than one percent, but an annual increase of at least almost 17 percent.
At Foot Locker, investors had to cope with a pre-market price loss of over six percent after the recent soaring and business figures. The sports retailer was able to increase sales on comparable retail space in the third quarter compared to the previous year. The net result collapsed, however. In addition, the CFO assumes that the global supply chain problems will continue to make themselves felt in the final quarter.
At the semiconductor company Applied Materials, the market also played it safe after the record hunt for shares and initially sold them: The price fell by almost six percent. In addition, analysts were disappointed with the business development in the past quarter and the outlook for the current quarter. The fact that, according to the unanimous assessment, supply chain problems were primarily responsible for this and that demand is still high, did not help the titles.
The shares of the big oil companies suffered further from the fall in the price of the important commodity: Chevron and Exxon Mobil fell in price by more than two percent each.
In contrast, Moderna stocks benefited with a price jump of five and a half percent from the fact that the US drug agency FDA approved corona booster vaccinations with the vaccine of the American Biontech competitor. Its shares, which are listed in New York, showed a plus of a good two percent. According to the company, the FDA has promised an accelerated approval process for a skin cancer vaccine candidate from Mainz if clinical studies are successful./gl/mis
– .
